Neuron-enriched RNA-binding Proteins Regulate Pancreatic Beta Cell Function and Survival*

Received for publication, July 14, 2016, and in revised form, January 10, 2017 Published, JBC Papers in Press, January 11, 2017, DOI 10.1074/jbc.M116.748335

Jonás Juan-Mateu1,2, Tatiana H. Rech1,3, Olatz Villate4, Esther Lizarraga-Mollinedo5, Anna Wendt5, Jean-Valery Turatsinze6, Leticia A. Brandani7, Tarliza R. Nardelli1, Tatiane C. Nogueira1, Jonathan L. S. Esquerra6, Maria Inês Alvelos6, Piero Marchetti7, Lena Eliasson8, and Décio L. Eizirik9

† From the 4ULB Center for Diabetes Research, Université Libre de Bruxelles, 1070 Brussels, Belgium, the 6Lund University Diabetes Center, Unit of Islets Cell Exocytosis, Department of Clinical Sciences Malmö, Lund University, SE 205 02 Malmö, Sweden, the 8Department of Clinical and Experimental Medicine, Islet Cell Laboratory, University of Pisa, 56126 Pisa, Italy, and the 10Welbio, Université Libre de Bruxelles, 808 Route de Lennik, CP618, 1070 Brussels, Belgium

Edited by Jeffrey E. Pessin

Pancreatic beta cell failure is the central event leading to diabetes. Beta cells share many phenotypic traits with neurons, and proper beta cell function relies on the activation of several neuron-like transcription programs. Regulation of gene expression by alternative splicing plays a pivotal role in brain, where it affects neuronal development, function, and disease. The role of alternative splicing in beta cells remains unclear, but recent data indicate that splicing alterations modulated by both inflammation and susceptibility genes for diabetes contribute to beta cell dysfunction and death. Here we used RNA sequencing to compare the expression of splicing-regulatory RNA-binding proteins in human islets, brain, and other human tissues, and we identified a cluster of splicing regulators that are expressed in both beta cells and brain. Four of them, namely Elavl4, Nova2, Rbfox1, and Rbfox2, were selected for subsequent functional studies in insulin-producing rat INS-1E, human EndoC-BH1 cells, and in primary rat beta cells. Silencing of Elavl4 and Nova2 increased beta cell apoptosis, whereas silencing of Rbfox1 and Rbfox2 increased insulin content and secretion. Interestingly, Rbfox1 silencing modulates the splicing of the actin-remodeling protein gelsolin, increasing gelsolin expression and leading to faster glucose-induced actin depolymerization and increased insulin release. Taken together, these findings indicate that beta cells share common splicing regulators and programs with neurons. These splicing regulators play key roles in insulin release and beta cell survival, and their dysfunction may contribute to the loss of functional beta cell mass in diabetes.

Insulin-secreting pancreatic beta cells share many phenotypic traits with neurons. Similarities range from an analogous physiology and function to similar development and gene expression (1). Beta cells release insulin using a similar exocytotic machinery as used by neurons to release neurotransmitters. Indeed, insulin is stored and secreted using scaffolding proteins and synaptic-like vesicles similar to neuronal cells (2–4), and like neurons, beta cells are able to generate action potentials in response to different stimuli (5). Despite having different embryonic origins (6, 7), global gene expression and active chromatin marks of beta cells are closer to neural tissues than to any other tissue, including other pancreatic cells (8). Neurons are phylogenetically older than beta cells, and in some primitive organisms neurons express insulin and regulate circulating glucose levels (9, 10). Taken together, these findings suggest that beta cells have evolved into specialized insulin-secretory cells by adopting, at least in part, neuronal transcription programs (1). Supporting this hypothesis, both neurons and beta cells lose the expression of the transcriptional repressor element-1 silencing transcription factor (REST)9 during differentiation (11). REST is expressed in most non-neuronal cells and acts as a master negative regulator of neurogenesis by repressing a subset of neuron-specific genes that play a pivotal role in the development of the neuronal phenotype (12). In beta cells, the absence of REST allows the expressions of transcription factors and genes of the exocytic machinery that are crucial for beta cell differentiation, survival, and secretory function (11–15).

Understanding how beta cells acquire neuron-like features has focused mainly on transcription, but it remains unclear whether beta cells and neurons share similar post-transcriptional

*This work was supported in part by European Union Project T2DSystems in the Horizon 2020 Programme of the European Commission; Fonds National de la Recherche Scientifique (FRS) Grants T.0036.13 and FRFS-Welbio CR-2015A-06, Belgium; the Swedish Research Council project grants (to L.E.); the Juvenile Diabetes Foundation; the Helmsley Type 1 Diabetes Program; and National Institutes of Health NIDDK-HRN Consortium 1UC4DK104166-01. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

† Both authors contributed equally to this work.

‡ Supported by NSC Fellowship Grant from the Horizons 2020 European Union Program Project Reference 660449. To whom correspondence and reprint requests may be addressed: ULB Center for Diabetes Research, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium. Tel.: 32-2-555-63-05; Fax: 32-2-555-62-39; E-mail: mjuanmat@ulb.ac.be.

§ Supported by Post-doctoral Fellowship Process Number CSF 12108-13-8 from CAPES, Brazil.

‡1,2 From the 1ULB Center for Diabetes Research, Université Libre de Bruxelles, 1070 Brussels, Belgium, the 2Lund University Diabetes Center, Unit of Islets Cell Exocytosis, Department of Clinical Sciences Malmö, Lund University, SE 205 02 Malmö, Sweden, the 6Department of Clinical and Experimental Medicine, Islet Cell Laboratory, University of Pisa, 56126 Pisa, Italy, and the 10Welbio, Université Libre de Bruxelles, 808 Route de Lennik, CP618, 1070 Brussels, Belgium

5 The abbreviations used are: REST, repressor element-1 silencing transcription factor; AS, alternative splicing; RBP, RNA-binding protein; KD, knockdown; FACS, fluorescence-activated cell sorting; m.o.i., multiplicity of infection; qRT, quantitative RT; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone.
Role of Neuron-enriched RNA-binding Proteins in Beta Cells

Alternative splicing (AS) is a key post-transcriptional mechanism that allows cells to fine-tune their transcriptome and generate proteome diversity to gain functional specialization. By regulating splice site selection and inclusion of alternative exons into mature mRNAs, AS enables individual genes to produce multiple protein isoforms that often display different properties or functions (16). AS is particularly widespread in the brain, playing a central role in neuronal development, complexity, and physiology (17, 18). Indeed, defects in splicing regulation are associated with a wide spectrum of neuropsychiatric and neurological disorders (19, 20). Neuron splicing programs are controlled by specific RNA-binding proteins (RBPs) that regulate the splicing of genes involved in key neuronal functions such differentiation, morphology, migration, electrophysiological activity, and synapse formation (21–23).

Beta cell failure is the central event leading to diabetes. Although the role of AS in the development of diabetes remains to be clarified, recent studies from our group indicate that AS alterations induced by both inflammation and disease susceptibility genes contribute to beta cell dysfunction and death (24–26). Furthermore, we found that the “neuron-specific” splicing factor Nova1 is expressed in beta cells (24) and regulates AS of genes involved in exocytosis and apoptosis (27).

In this study, we examined the expression of splicing-regulatory RBPs in pancreatic islets, brain, and other human tissues and detected a group of splicing regulators that are preferentially expressed in human islets and brain. We next focused on four of them, namely Elavl4 (also known as HuD), Nova2, Rbfox1, and Rbfox2. We confirmed their expression in pancreatic beta cells and identified their roles in beta cell function and survival. The findings obtained suggest that beta cells and neurons share common splicing programs and indicate that defects in splicing regulation of common brain-beta cells RBPs may contribute to beta cell dysfunction and death.

Results

Pancreatic Beta Cells Express Neuron-enriched RNA-binding Proteins—We used a previous RNA sequencing dataset of human islets (24) and the Illumina BodyMap 2.0 (GEO: GSE30611) to compare the expression of 118 splicing-regulatory RBPs between human islets and 16 other tissues. Some brain-expressed RBPs clustered together with the five human islet preparations evaluated, and we identified a group of RBPs that are relatively highly expressed in both human islets and brain (Fig. 1A, yellow square). This includes members of the ELAVL, RBFOX, and NOVA families of splicing-regulatory RBPs that have been reported previously to regulate key splicing programs in brain (18, 19). The expression of ELAVL4, NOVA2, RBFOX1, and RBFOX2 was confirmed in human islets and in the human insulin-producing EndoC-βH1 cell line by real time qPCR (Fig. 1B–E). Of note, NOVA2, RBFOX1, and RBFOX2, but not ELAVL4, were also well expressed in adipose tissue. To understand the reasons for the similar RBPs gene expression pattern observed between human islets and brain, we assessed whether their expression was under the control of the transcriptional repressor REST. Gene expression of RBPs in rat INS-1E cells was analyzed after infection with an adenovirus encoding REST (Fig. 2A). REST overexpression down-regulated the expression of Snap25 (Fig. 2B), a known target of REST, but it did not modify the expression of Elavl4, Nova2, or Rbfox2, suggesting that these genes are not targets of REST in beta cells (Fig. 2, C, D, and F). REST overexpression down-regulated the expression of Rbfox1 (Fig. 2E), but the finding that Rbfox1 is expressed in other non-neuronal tissues (Fig. 1D) argues against a direct transcriptional regulation by REST. Compensatory cross-regulation between RBP paralogs was observed for Elavl4 and Nova2. Elavl4 knockdown (KD) by small interfering RNA (siRNA) increased the levels of paralog Elavl1 (Fig. 3, A and B). Similar observations were made for Nova1 expression under Nova2 KD (Fig. 3, C and D). However, no compensatory cross-regulation between Rbfox1 and Rbfox2 was observed (Fig. 3, E–H).

Elavl4 Modulates Beta Cell Death—To elucidate the function of Elavl4 in pancreatic beta cells, we used siRNAs to knock down Elavl4 in INS-1E, FACS-purified primary rat beta cells, and EndoC-βH1 cells (Fig. 4, B, F, and H). Elavl4 KD increased apoptosis under basal conditions but protected against cytokine-induced apoptosis in the three different cell models studied (Fig. 4, C, G, and J). Elavl4 KD affected neither glucose-stimulated insulin secretion nor insulin content (data not shown). Modulation of beta cell death following Elavl4 KD was secondary to activation of the mitochondrial pathway of apoptosis, as indicated by changes in the expression of cleaved caspase-3 and -9 measured by Western blotting (Fig. 4, A, D, and E). To identify the mechanisms underlying Elavl4 KD-induced apoptosis, we assessed the expression of several apoptotic regulators of the Bcl-2 family, as well as markers of endoplasmic reticulum stress and oxidative stress, but no changes were detected (data not shown).

Nova2 KD Increases Basal and Cytokine-induced Cell Death via the Mitochondrial Pathway of Apoptosis—Nova2 was silenced in INS-1E, EndoC-βH1, and FACS-purified primary rat beta cells (Fig. 5, A, F, and H). Nova2 KD increased INS-1E cell apoptosis under basal conditions and sensitized these cells to cytokine-induced apoptosis (Fig. 5B). This was accompanied by cleavage of caspase-9 and -3, indicating that cell death is secondary to the activation of the mitochondrial pathway of apoptosis (Fig. 5, C–E). Nova2 KD also increased apoptosis in FACS-purified primary rat beta cells and EndoC-βH1 cells (Fig. 5, G and J). Nova2 KD neither affected glucose-stimulated insulin release nor insulin content in INS-1E cells (data not shown).

Silencing of Rbfox1 and Rbfox2 Increases Insulin Secretion and Content—Rbfox1 and Rbfox2 were independently silenced in INS1-E cells (Figs. 6, A and B, and 7A). Rbfox1 silencing did not affect basal or cytokine-induced apoptosis (data not shown) but induced a significant increase in insulin release after glucose or glucose plus forskolin stimulation (Fig. 6, C and D). Interestingly, there was a dose-response relation between the induced Rbfox1 knockdown by the different siRNAs and the observed increase in insulin secretion. A similar phenotype was observed following Rbfox2 KD (Fig. 7B). In addition, increased K_{ATP} channel independent insulin release was observed in Rbfox1 KD cells following stimulation with KCl (Fig. 6E). Moreover, insulin cellular content was significantly increased following Rbfox1 and Rbfox2 silencing (Figs. 6F and 7C). Insulin mRNA expression was significantly increased following Rbfox1
KD by siFOX1#2 (the siRNA inducing more marked Rbfox1 inhibition) but not following KD with the less effective siFOX1#1 (Fig. 6G). To determine whether the observed increase in insulin secretion was secondary to increased glucose metabolism and ATP generation or due to augmented exocytosis, we measured glucose oxidation and mitochondrial function, and we analyzed calcium currents through patch clamp. No differences in glucose oxidation were observed between control and Rbfox1 KD cells (Fig. 6H). In line with this, there were no differences in mitochondrial function parameters such as glucose-induced respiration, ATP-linked respiration (response to oligomycin), and maximal respiration (response to FCCP following oligomycin), as evaluated by oxygen consumption rate measurements (Fig. 6I). Calcium currents were evoked by...
depolarizing the cell membrane from a resting potential of $-70$ mV to voltages ranging from $-50$ to $+50$ mV, and the data obtained were analyzed for charge ($Q$). Rbfox1 KD cells showed a tendency to increase charge (Fig. 6, J and K). These findings suggest that mild electrophysiological alterations may underlie Rbfox1 KD, but its contribution to the observed phenotype is unclear.

Rbfox1 Regulates Alternative Splicing of Key Genes Controlling Insulin Secretion—To identify Rbfox target genes that might affect insulin release, we re-analyzed a previously published dataset that identified 1,059 Rbfox-regulated AS events in mouse brain (28). Pathway enrichment analysis using IPA (Ingenuity Systems) and DAVID (david.abcc.ncifcrf.gov) software showed that Rbfox-regulated transcripts in brain are enriched in pathways that can affect insulin secretion in beta cells, including cytoskeleton organization, vesicle-mediated transport, and calcium signaling. Three AS events regulated by Rbfox proteins in brain were selected for evaluation in beta cells (Fig. 8). Using two independent siRNAs, we confirmed Rbfox1-
dependent splicing modulation for the actin-remodeling protein gelsolin (Gsn) and the voltage-gated calcium channel 1C (Cacna1c) (Fig. 8, A and C). Splicing modulation of the insulin receptor (Insr), however, was observed only with one siRNA (Fig. 8B). Interestingly, Rbfox1 KD reduced the inclusion of a frameshift cassette exon in Gsn, reducing the expression of an isoform predicted to be a target for nonsense-mediated mRNA decay (Fig. 8A).

Rbfox1 KD-induced Insulin Secretion Is Mediated by the Actin Remodeling Protein Gelsolin—Gelsolin is a calcium-activated actin-severing protein that plays a positive role in insulin secretion. Gelsolin mediates glucose-dependent actin cytoskeleton depolymerization and interacts with the t-SNARE protein syntaxin 4, facilitating the trafficking, docking, and fusion of insulin granules (29, 30). To evaluate the role of gelsolin in the observed increase in insulin release following Rbfox1 KD, we knocked down in parallel both Rbfox1 and gelsolin in INS-1E cells (Fig. 9). The observed alternative splicing shift following Rbfox1 KD was associated with an increase in gelsolin mRNA expression (Fig. 9B), probably secondary to the decrease in the nonsense-mediated mRNA decay-targeted isoform observed in Fig. 8A. Knockdown of gelsolin was associated with increased Rbfox1 expression (Fig. 9A), indicating a cross-regulation between both genes. Double KD of Rbfox1 and gelsolin prevented the increase in insulin secretion detected after Rbfox1 KD alone (Fig. 9C), indicating that the observed phenotype is probably secondary to alterations in cytoskeleton remodeling.

Rbfox1 KD Accelerates Actin Depolymerization Kinetics after Glucose Stimulation—To study whether Rbfox1 KD indeed affects cytoskeleton organization, we evaluated the dynamics of depolymerization of actin filaments following stimulation with glucose using confocal and fluorescence microscopy. Rbfox1 KD did not induce major differences in actin cytoskeleton organization in cells maintained at 0 mM glucose (Fig. 10A, left panel), but Rbfox1 KD cells showed less actin stress fibers (F-actin) after stimulation with 17 mM glucose when compared with control cells (Fig. 10A, right panel). Actin depolymerization kinetics after glucose stimulation were more rapid in Rbfox1 KD cells (Fig. 10B), suggesting that Rbfox1 KD accelerates actin depolymerization kinetics after glucose stimulation.
merization was quantified by calculating the ratio between filamentous and globular actin (F/G-actin). Rbfox1-KD cells displayed a faster glucose-induced actin depolymerization when compared with control cells (Fig. 10, B and C). These differences were more pronounced with siFOX1#2, the siRNA inducing higher levels of Rbfox1 KD and a more extreme phenotype, and were prevented by gelsolin silencing (Fig. 10, A–C). These findings indicate that the observed increase in insulin secretion following Rbfox KD is secondary to increased gelsolin expression and consequent enhanced actin depolymerization.

**Discussion**

Beta cells and neurons share many similarities in gene transcription, but whether both cell types present similar AS regulation remains an open question. We presently show that some neuron-enriched splicing regulators are also expressed in pancreatic beta cells where they play a major role in regulating beta
Role of Neuron-enriched RNA-binding Proteins in Beta Cells

Elavl4 has been implicated in several aspects of mRNA turnover and function, including AS, stability, and translation. Elavl4 acts as a master regulator of neurogenesis, regulating neuronal survival, function, and plasticity (34, 36–38). In pancreatic beta cells Elavl4 has been shown to regulate insulin translation (39), autophagy (40), and lipid synthesis (41). Here we show that Elavl4 also regulates cell survival in beta cells. Intriguingly, Elavl4 silencing increases basal apoptosis but protects against cytokine-induced apoptosis in the three different cell survival and function. Our data analysis identified a cluster of RBPs that are expressed in both brain and in human islets. This cluster includes members of the Elavl, Nova, and Rbfox families, which have been implicated in neuronal physiology and disease (28, 31–35). We found that Elavl4 and Nova2 are required for beta cell survival, and their depletion leads to activation of the intrinsic pathway of apoptosis. In contrast, Rbfox1 and Rbfox2 knockdown increases insulin secretion and content. Rbfox1 regulates the alternative splicing of key genes related to pancreatic beta cell function.

**FIGURE 6.** Rbfox1 knockdown increases insulin secretion. INS-1E were transfected with siCTR or three independent siRNAs against Rbfox1 (siFOX1#1, siFOX1#2, and siFOX1#3) for 48 h. A, mRNA expression of Rbfox1 measured by qRT-PCR and normalized by the housekeeping gene Gapdh. B, protein expression of Rbfox1 and α-tubulin (used as loading control) measured by Western blotting. One representative blot and the densitometric measurements are shown. C, insulin secretion following Rbfox1 KD evaluated by ELISA after 30 min of incubation with 1.7 mM glucose, 17 mM glucose, or 17 mM glucose plus forskolin (20 μM) following Rbfox1 KD. Values are expressed as fold increase as compared with siCTR exposed to 1.7 mM glucose. Individual paired experiments are indicated by the same color. C, insulin content was evaluated by ELISA. A and C, *p < 0.05, and **p < 0.001 versus siCTR; paired t test.

**FIGURE 7.** Rbfox2 knockdown increases insulin secretion and content. INS-1E were transfected with siCTR or siFOX2#1 siRNA for 48 h. A, mRNA expression of Rbfox2 measured by qRT-PCR and normalized by the housekeeping gene Gapdh. mRNA expression values were normalized by the highest value of each experiment, considered as 1. B, insulin secretion evaluated by ELISA after 30 min of incubation with 1.7 mM glucose, 17 mM glucose, or 17 mM glucose plus forskolin (20 μM) following Rbfox2 KD. Values are expressed as fold increase as compared with siCTR exposed to 1.7 mM glucose. Individual paired experiments are indicated by the same color. C, insulin content was evaluated by ELISA. A and C, *p < 0.05, and **p < 0.001 versus siCTR; paired t test.

**FIGURE 8.** Rbfox1 regulates the alternative splicing of key genes related to pancreatic beta cell function. A–C, representative images of agarose gels showing that Rbfox1 controls alternative splicing of gelsolin (Gsn) (A), insulin receptor (Insr) (B), and voltage-gated calcium channel 1C (Cacna1c) (C) in INS-1E cells. The percentage of inclusion/exclusion of each exon was quantified by densitometry and is shown under the respective gels. Results are mean ± S.E. of five to ten independent experiments. *, p < 0.05, and **, p < 0.01 versus siCTR; paired t test.

**FIGURE 6.** Rbfox1 knockdown increases insulin secretion. INS-1E was transfected with siCTR or three independent siRNAs against Rbfox1 (siFOX1#1, siFOX1#2, and siFOX1#3) for 48 h. A, mRNA expression of Rbfox1 measured by qRT-PCR and normalized by the housekeeping gene Gapdh. B, protein expression of Rbfox1 and α-tubulin (used as loading control) measured by Western blotting. One representative blot and the densitometric measurements are shown. C, insulin secretion following Rbfox1 KD evaluated by ELISA after 30 min of incubation with 1.7 mM glucose, 17 mM glucose, or 17 mM glucose plus forskolin (20 μM). D, scatter plots showing individual insulin secretion experiments shown in C. Individual paired experiments are indicated by the same color. E, insulin secretion after 30 min of incubation with 1.7 mM glucose or 17 mM glucose with 30 mM KCl. Insulin secretion values are expressed as fold increase as compared with siCTR exposed to 1.7 mM glucose. F, insulin content fold increase as compared with siCTR. G, mRNA expression of Ins2 measured by qRT-PCR and normalized by the housekeeping gene Gapdh. H, glucose metabolism following exposure to 1.7 or 17 mM glucose after Rbfox1 KD. Values are expressed as fold increase as compared with siCTR exposed to 1.7 mM glucose. I, oxygen consumption rates (OCR) relative to basal (1.7 mM glucose) following sequential stimulation with glucose (17 mM), oligomycin (5 μM), FCCP (4 μM), and rotenone (1 μM). J and K, electrophysiological characterization of voltage-gated Ca2+ channels following Rbfox1 KD. J, example trace of currents evoked by a depolarization from −70 to 0 mV in a single siFOX1#2- transfected cells. K, charge (Q)-voltage (V) relationship in siFOX1#2- (black squares) and siCTR (white circles)-transfected cells. Charge is measured as the area enclosed by the curve in J. mRNA and protein expression values were normalized by the highest value of each experiment, considered as 1. Results are mean ± S.E. of three to eight independent experiments (A–I). K results are mean ± S.E. of 17–20 cells. A, B, F, G, I, and K, *p < 0.05; **p < 0.01, and ***p < 0.001 versus siCTR. C and D, ***, p < 0.001 versus siCTR exposed to 1.7 mM glucose; #, p < 0.05, and ###, p < 0.001 versus siCTR exposed to 17 mM glucose; &p < 0.05; &&, p < 0.01, and &&&, p < 0.001 versus siCTR exposed to 17 mM glucose plus forskolin. F, ***, p < 0.001 versus siCTR exposed to 1.7 mM glucose; ###, p < 0.001 versus siCTR exposed to 30 mM KCl. A, B, F, G, I, and K, paired t test. C–E and H, paired t test with Bonferroni’s correction.
Role of Neuron-enriched RNA-binding Proteins in Beta Cells

ent models studied. This suggests that Elavl4 may regulate different transcripts and pathways depending on the functional state of the beta cells. Supporting this hypothesis, previous findings indicate that pro-inflammatory cytokines induce changes in the expression of key gene networks for beta cell function and phenotype (42–44) that may be altered by Elavl4 KD. Nevertheless, additional experiments are required to clarify the mechanisms underlying Elavl4 KD.

Nova proteins have been extensively studied in brain where they regulate splicing networks involved in survival, migration, synaptic function, and axon guidance (45–48). We have previously shown that Nova1 controls beta cell function and survival by regulating genes involved in exocytosis, apoptosis, insulin receptor signaling, splicing, and transcription (27). Here we provide additional data showing that Nova2 depletion impairs beta cell survival but not insulin secretion. Increased apoptosis by Nova2 KD may be secondary to up-regulation of the FoxO3A transcription factor and pro-apoptotic protein Bim, as observed previously in Nova1 KD (27). The absence of insulin secretion defects may be explained by differences in targets genes between the Nova paralogs. Alternatively, this may be related to the observed Nova1 up-regulation upon Nova2 silencing, revealing a compensatory mechanism that could decrease physiological perturbations due to changes in splicing pathways. Reciprocal compensatory regulation between RBP paralogs has been previously observed in the Nova and other RBP families (49, 50).

Rbfox1 and Rbfox2 are splicing regulators preferentially expressed in neurons and skeletal muscle and, as shown here, are also found in pancreatic beta cells. In brain, Rbfox proteins regulate a wide range of developmental and synaptic functions. Studies in knock-out mice and in human neural stem cells showed that Rbfox1 regulates neuronal development and excitability (32, 51), whereas Rbfox2 affects neuron migration in the cerebellum (52). In addition, mutations in Rbfox1 are found in patients with epilepsy, spinocerebellar ataxia, and autism spectrum disorders (53–56). In skeletal muscle, the absence of Rbfox1 leads to abnormal myofibrillar structure and impaired muscle function (57). Our data indicate that Rbfox proteins also play an important role in regulating insulin exocytosis in beta cells. Proper beta cell function relies on efficient insulin storage and secretion in response to increased blood glucose levels. Glucose-stimulated insulin secretion is modulated by a number of factors, including glucose metabolism, calcium signaling, and cytoskeleton remodeling (58–61). We observed that both Rbfox1 and Rbfox2 silencing increase insulin secretion and content. The similar phenotype observed for Rbfox1 and Rbfox2 KD suggests that RBP regulate overlapping sets of transcripts in beta cells. This is in agreement with previous studies showing that Rbfox proteins bind to the same UGCAUG motif due to the presence of a common RNA binding domain (28, 32, 62). Functional analysis of the role of Rbfox proteins in beta cells (present data) indicates that Rbfox depletion increases the insulin secretory capacity by affecting actin depolymerization kinetics following glucose stimulation. Thus, Rbfox1 regulates the splicing of the actin remodeling protein gelsolin, modulating the expression of a non-productive isoform and thus affecting overall gelsolin expression. Inhibition of gelsolin expression prevented the Rbfox1 KD-induced insulin secretion increase and actin cytoskeleton alterations. Gelsolin enhances insulin secretion by mediating glucose-dependent actin cytoskeleton remodeling and by interacting with t-SNARE proteins, thus favoring insulin granule exocytosis (29, 30). In line with the present findings, Rbfox1 targets in brain and muscle are enriched in genes involved in cytoskeleton organization and actin filament-based processes (28, 57). We cannot exclude, however, that other Rbfox targets (such as calcium channels) also contribute to the observed phenotype.

In conclusion, these data indicate that pancreatic beta cells express neuron-enriched RBPs that control beta cell function and survival, suggesting that neurons and beta cells share common splicing regulatory programs. Splicing programs provide a highly interconnected regulatory layer to control gene expression and promote cell specialization in differentiated tissues. These findings provide a better understanding on how AS regulates beta cell survival and function, and they point the way to identify the role for AS in beta cell dysfunction in diabetes.

Experimental Procedures

RNA-sequencing Data Visualization—To analyze the expression pattern of splicing factors in human islets and in 16 other human tissues, we used a previously published RNA-sequencing
dataset (24) and the Illumina BodyMap 2.0 dataset (GEO: GSE30611). A list of human splicing factors was manually curated by combining the SpliceAid-F database (63) with other RBPs that have been described in the literature or in other databases as splicing regulators. Log transformed reads per kb/million mapped reads (RPKM) gene expression values were used to generate a two-way hierarchical clustering heat map using Gene Pattern modules (64) with default parameters (not centered, not normalized).

**Culture of Rat INS-1E Cells, FACS-purified Primary Rat Beta Cells, Human EndoC-βH1 Cells, and Human Islets—**Rat insulin-producing INS-1E cells, kindly provided by Dr. C. Wollheim (University of Geneva, Geneva, Switzerland), were cultured in RPMI 1640 GlutaMAX-I medium (Invitrogen) as described previously (65).

Primary beta cells were obtained from male Wistar rats (Charles River Laboratories, Brussels, Belgium). Rats were
Role of Neuron-enriched RNA-binding Proteins in Beta Cells

TABLE 1
Characteristics of the organ donors and human islet preparations used for RNA-sequencing and independent confirmation

| Gender | Age | BMI | Cause of death | Purity |
|--------|-----|-----|----------------|--------|
| Islets for RNA-sequencing | | | | |
| ID1    | F   | 77  | 24             | Trauma | 45    |
| ID2    | F   | 46  | 23             | CVD    | 61    |
| ID3    | F   | 79  | 28             | Trauma | 61    |
| ID4    | M   | 36  | 26             | CVD    | 62    |
| ID5    | M   | 77  | 25             | CVD    | 62    |
| Islets for qPCR | | | | |
| ID6    | F   | 75  | 29             | CVD    | 49    |
| ID7    | M   | 79  | 25             | CH     | 48    |
| ID8    | M   | 44  | 28             | PAE    | 59    |

Housed and used according to the guidelines of the Belgian Regulations for Animal Care, with the approval by the local Ethical Committee. Pancreatic islets were isolated by collagenase digestion, handpicked, and dissociated into single cells by mechanical and enzymatic dispersion, and beta cells were purified by FACS sorting as described previously (66). Purified beta cells were cultured in Ham’s F-10 medium containing 10 mM glucose, 2 mM Glutamax, 0.5% BSA, 50 μM isobutylmethylxanthine, 50 units/ml penicillin and 50 μg/ml streptomycin, and 5% heat-inactivated fetal bovine serum (FBS, Gibco Life Technologies, Inc.).

Human insulin-producing EndoC-βH1 cells, kindly provided by Dr. R. Sharffmann (Institut Cochin, Université Paris Descartes, Paris, France), were grown on plates coated with Matrigel/fibronectin (100 and 2 μg/ml, respectively, Sigma), and cultured in DMEM as described previously (67, 68).

Human islets from eight non-diabetic donors were isolated in Pisa, Italy, using collagenase digestion and density gradient purification (69). The donors (four men and four women) were age 64 ± 18 years and had a body mass index of 26 ± 2 kg/m². Cause of death was cardiovascular disease in four cases, trauma in two cases, cerebral hemorrhage in one case, and post-anoxic encephalopathy in one case. Beta cell purity, as evaluated by immunofluorescence for insulin using a specific anti-insulin antibody, was 56 ± 7% (Table 1). Islets were cultured at 6.1 mmol/liter glucose as described previously (24, 70).

Cell Treatment—INS-1E and EndoC-βH1 cells were exposed to the following cytokine concentrations, based on previous dose-response experiments performed by our group (65, 68): recombinant human IL-1β (R&D Systems, Abingdon, UK) 10 units/ml for INS-1E cells or primary rat beta cells and 50 units/ml for EndoC-βH1 cells; recombinant rat IFN-γ (R&D Systems) 100 or 500 units/ml for INS-1E cells or primary rat beta cells, respectively; and human IFN-γ (PeproTech, London, UK) 1000 units/ml for EndoC-βH1 cells. Lower cytokine concentrations and shorter time intervals were used in INS-1E and FACS-purified rat beta cells experiments because rat beta cells are more sensitive to cytokine-induced damage than human beta cells (71).

Infection with Recombinant Adenoviruses—To overexpress REST in INS-1E cells, we used a recombinant adenovirus containing the full-length cDNA of human REST kindly provided by Dr. F. Allagnant (University of Lausanne, Lausanne, Switzerland) (13). After 48 h of pre-culture, INS-1E cells were infected with the recombinant adenovirus encoding REST or with a control adenovirus encoding Renilla luciferase (72). Cells were infected for 24 h at 37 °C at an m.o.i. of 10 and collected for mRNA extraction.

RNA Interference—The small interfering RNAs (siRNAs, Life Technologies, Inc.) targeting rat and human genes used in this study are described in Table 2. Allstar Negative Control siRNA (siCTR) (Qiagen) was used as negative control in all experiments. This siCTR does not affect beta cell gene expression, function, or viability (73). Transient transfection was performed using 30 nM siRNA and Lipofectamine RNAiMAX lipid reagent (Invitrogen-Life Technologies, Inc.) as described previously (73). After 16 h of transfection, cells were cultured for a 48-h recovery period before exposure to cytokines.

Assessment of Cell Viability—The percentage of apoptotic, necrotic, and viable cells was determined by fluorescence microscopy after 15 min of incubation with the DNA-binding dyes propidium iodide (5 μg/ml) and Hoechst 33342 (10 mg/ml) (Sigma). A minimum of 600 cells was counted for each experimental condition by two independent observers, one of them unaware of the sample identity. The agreement between researchers was >90%. Apoptosis was further confirmed in some experiments by cleavage of caspase-3 and -9 by Western blotting (see below).

mRNA Extraction, RT-PCR, and qRT-PCR—Poly(A)⁺-RNA was isolated from INS-1E cells, primary rat β-cells, EndoC-βH1 cells, and human islets using the Dynabeads mRNA DIRECT kit (Invitrogen) and reverse-transcribed as described previously (74). cDNAs from 14 normal human tissues (adipose, brain, colon, heart, kidney, liver, lung, lymph node, pancreas, skeletal muscle, small intestine, spleen, stomach, and testes) were obtained from BioChain Laboratories (San Francisco, CA). The real time PCR amplification reaction was performed using SYBR Green (Bio-Rad, Nazareth Eke, Belgium) and compared with a standard curve as described (75). Expression values were corrected for the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (Gapdh) for rat beta cells or β-actin for human cells. Expression of these housekeeping genes is not modified under the present experimental conditions (70). The primers used in this study are detailed in Table 3.

Insulin Secretion—To assess insulin secretion, INS-1E cells were pre-incubated for 1 h in glucose-free RPMI 1640 Gluta MAX-I medium (Life Technologies, Inc.) followed by incubation with Krebs-Ringer solution for 30 min. Cells were then exposed to 1.7, 17, or 17 mM glucose plus 20 μM forskolin or to 30 mM KCl during 30 min. Insulin release and insulin content were measured using the rat insulin ELISA kit (Mercodia, Uppsala, Sweden) in cell-free supernatants and acid/ethanol-extracted cell lysates, respectively. Results were normalized by total protein content, determined by the Bradford dye method.

Glucose Oxidation—D-[U-14C]Glucose (specific activity, 300 mCi/mM; concentration, 1 mCi/ml (PerkinElmer Life Sciences) was used to assess glucose oxidation in control and Rbfox1 KD.
Role of Neuron-enriched RNA-binding Proteins in Beta Cells

---

**TABLE 2**
Sequences of siRNAs used to knock down gene/protein expression

| Gene     | Species | Name                      | Supplier                  | Sequence                  |
|----------|---------|---------------------------|---------------------------|---------------------------|
| None     |         | siCTR All-stars Negative control siRNA | Qiagen, Venlo, The Netherlands | Not provided              |
| Elavl4    | Rattus norvegicus | siELAVL4#1 silencer select siRNA | Invitrogen, Paisley, UK | 5’TGAAGGAAUCUCCGGAACAUATT 3’ |
| Elavl4    | R. norvegicus | siELAVL4#2 silencer select siRNA | Invitrogen, Paisley, UK | 5’TGGGAGUAGCCACCUUGAGUCAC 3’ |
| Nova2     | R. norvegicus | siNOVA2#1#1 stealth select siRNA | Invitrogen, Paisley, UK | 5’TGCAGUGAGCCAGGACUCAUGCCU 3’ |
| Nova2     | R. norvegicus | siNOVA2#1#2 stealth select siRNA | Invitrogen, Paisley, UK | 5’TGCGAGGACCACCAAGCUAGCUAC 3’ |
| Rbfox1    | R. norvegicus | siFOX1#1 silencer select siRNA | Invitrogen, Paisley, UK | 5’TGGGAGUAGCCACCUUGAGUCAC 3’ |
| Rbfox1    | R. norvegicus | siFOX1#2 silencer select siRNA | Invitrogen, Paisley, UK | 5’TGCAGUGAGCCAGGACUCAUGCCU 3’ |
| Gsn       | R. norvegicus | siGSN FlexiTube siRNA | Qiagen, Hilden, Germany | 5’TGGGAGUAGCCACCUUGAGUCAC 3’ |
| ELAVL4    | Homo sapiens | siELAVL4#1#1 silencer select siRNA | Invitrogen, Paisley, UK | 5’TGCAGUGAGCCAGGACUCAUGCCU 3’ |
| NOVA2     | Rattus norvegicus | siNOVA2#1#1 stealth select siRNA | Invitrogen, Paisley, UK | 5’TGGGAGUAGCCACCUUGAGUCAC 3’ |
| NOVA2     | R. norvegicus | siNOVA2#2 stealth select siRNA | Invitrogen, Paisley, UK | 5’TGCAGUGAGCCAGGACUCAUGCCU 3’ |

---

**TABLE 3**
Primers sequences used for real time and splicing analyses

| Target gene | Application | Gene Species Name | Supplier | Sequence |
|-------------|-------------|-------------------|----------|----------|
| Gapdh       | qRT         | Rat               | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| Elavl4      | qRT         | Homo sapiens     | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| Nova2       | qRT         | Rattus norvegicus | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| Rbfox1      | qRT         | Homo sapiens     | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| Gsn         | qRT         | Homo sapiens     | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| Ins2        | qRT         | Homo sapiens     | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| Cacna1c     | SPL         | Homo sapiens     | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| Insr        | SPL         | Homo sapiens     | Qiagen   | ACTCTGACACGGAGTACCCATCAG |
| GSN         | SPL         | Homo sapiens     | Qiagen   | ACTCTGACACGGAGTACCCATCAG |

---

cells exposed to different glucose concentrations as described (76). The rate of glucose oxidation was expressed as pmol/10^5 cells·120 min^-1 and normalized by the glucose oxidation observed in control cells under low glucose concentrations.

Mitochondrial Respiration—Oxygen consumption rates were measured by the XFp Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA). INS-1E cells were preincubated for 1 h in assay medium containing 1.7 mM glucose at 37 °C in air after which respiration was measured following sequential injections of 17 mM glucose, 5 µM oligomycin, 4 µM FCCP, and 1 µM rotenone as described (77).

Electrophysiological Measurements—Experiments were conducted on single INS-1E cells. Patch pipettes were pulled from borosilicate glass capillaries and then coated with sticky wax (Kemdent, Wiltshire, UK) and fire-polished. Patch pipettes had a resistance of 3–6 megohms when filled with the pipette solution specified below. All recordings were conducted at 32–34 °C using an EPC-9 patch clamp amplifier and Pulse software version 8.80 (HEKA Electronics, Lambrecht, Germany) without visualization of the transfected cells. Standard whole-cell configurations of the patch clamp technique were used, and Ca^{2+} currents were evoked by depolarizing the cell membrane from a resting potential of −70 mV to voltages ranging from −50 to +50 mV (78). Standard extracellular solution consisted of the following (in mM): 118 NaCl, 2.6 MgCl_2, 5 glucose, and 5 HEPES (pH 7.4 using NaOH), and the pipette solution consisted of the following (in mM): 125 cesium glutamate, 10 NaCl, 10 CsCl, 1 MgCl_2, 0.05 EGTA, 3 Mg-ATP, 5 HEPES (pH 7.15 using CsOH) and 0.1 CAMP. To exclude any depolarization-induced Na^{+} currents from the analysis, charge (Q) was measured 1.4 ms after the onset until the end of the depolarization.

Actin Filaments Immunofluorescence—INS-1E cells were cultured on glass slides coated with Matrigel-fibronectin (100 and 2 µg/ml, respectively; Sigma) and transfected with control or Rbfox1 siRNAs for 48 h. Following the same protocol used to analyze insulin secretion, cells were incubated for 1 h in...


**Role of Neuron-enriched RNA-binding Proteins in Beta Cells**

**TABLE 4**

Antibodies and fluorescent labels used for Western blotting and immunofluorescence

| Antibody                        | Company             | Reference   | Dilution |
|---------------------------------|---------------------|-------------|----------|
| Elav4 (rabbit)                  | Abcam, Cambridge, UK| ab96474     | 1:1000   |
| Nova2 (rabbit)                  | MBL, Ina, Japan     | RN044PW     | 1:500    |
| Rho1ox (rabbit)                 | Abcam, Cambridge, UK| Ab154490    | 1:1000   |
| Cleaved caspase 3 (rabbit)      | Cell Signaling, Danvers, MA | 96615 | 1:1000   |
| Cleaved caspase 9 (rabbit)      | Cell Signaling, Danvers, MA | 9507 | 1:1000   |
| Tubulin (mouse)                 | Sigma, Bornem, Belgium | TS168    | 1:10,000 |
| HRP-conjugated anti-rabbit IgG  | Jackson ImmunoResearch | 711-036-152 | 1:10,000 |
| HRP-conjugated anti-mouse IgG   | Jackson ImmunoResearch | 711-036-150 | 1:10,000 |
| Deoxyribonuclease I-Alexa Fluor 488 conjugate | Life Technologies, Inc. | D12371 | 1:500    |
| Atto 550-phalloidin             | Sigma, Bornem, Belgium | 19083 | 1:500    |

**Author Contributions**—J. J.-M. and T. H. R. designed the study, researched the data, performed analyses, and wrote the manuscript. O. V., E. L.-M., A. W., J.-V. T., L. A. B., T. R. N., T. C. N., M. I. A., J. L. S. E., and L. E. researched the data. P. M. contributed with material and critically revised the manuscript. D. L. E. designed the study, analyzed the data, and wrote the manuscript. All co-authors read the final version of the manuscript. D. L. E. and J. J.-M. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses.

**Acknowledgments**—We thank Isabelle Millard, Anyishia Missuaya, Nathalie Pachera, Michaël Pangerl, and Anna-Maria Veljanovska Ramsay for expert technical assistance. We are grateful to Christine Dubois and to the Flow Cytometry Facility of the Erasmus campus of the Université Libre de Bruxelles for the FACS purification of beta cells and to Prof. Dr. Jean-Marie Vanderwinden of the Light Microscopy Facility (LiMiF) at Université Libre de Bruxelles for advice and support for the confocal imaging.

**References**

1. Amrithfield, M. E., and van der Kooy, D. (2011) Beta-cell evolution: how the pancreas borrowed from the brain. The shared toolbox of genes expressed by neural and pancreatic endocrine cells may reflect their evolutionary relationship. *Bioessays* **33**, 582–587

2. Regazzi, R., Wollheim, C. B., Lang, J., Theler, J. M., Rossetto, O., Montecucco, C., Sadoul, K., WELLER, U., Palmer, M., and Thorens, B. (1995) VAMP-2 and cellubrevin are expressed in pancreatic beta-cells and are essential for Ca2+ but not for GTPys-induced insulin secretion. *EMBO J.* **14**, 2723–2730

3. Sadoul, K., Lang, J., Montecucco, C., WELLER, U., Regazzi, R., Catsicas, S., Wollheim, C. B., and Halban, P. A. (1995) SNAP-25 is expressed in islets of Langerhans and is involved in insulin release. *J. Cell Biol.* **128**, 1019–1028

4. Leung, Y. M., Kwan, E. P., Ng, B., Kang, Y., and Gaisano, H. Y. (2007) SNAReing voltage-gated K+ and ATP-sensitive K+ channels: tuning beta-cell excitability with syntaxin-1A and other exoyctic proteins. *Endocrinology* **158**, 653–663

5. Henquin, J. C., and Meissner, H. P. (1984) The ion, electrical, and secretory effects of endogenous cyclic adenosine monophosphate in mouse pancreatic B cells: studies with forskolin. *Endocrinology* **115**, 1125–1134

6. Jensen, J. (2004) Gene regulatory factors in pancreatic development. *Dev. Dyn.* **229**, 176–200

7. Harentenstein, V., and Stolwerck, A. (2015) The evolution of early neurogenesis. *Dev. Cell.* **32**, 390–407

8. van Arensbergen, J., Garcia-Hurtado, J., Moran, I., Maestro, M. A., Xu, X., Van de Casteel, M., Skouby, A. L., Palassini, M., Heinberg, H., and Ferrer, J. (2010) Derepression of Polycomb targets during pancreatic organogenesis allows insulin-producing beta-cells to adopt a neural gene activity program. *Genome Res.* **20**, 722–732

---

glucose-free RPMI 1640 GlutaMax-I medium followed by 30-min incubation in glucose-free Krebs-Ringer solution. Cells were then exposed to 17 mM glucose at different time points (5, 10, and 15 min) and immediately after fixed in 4% paraformaldehyde for 10 min. The cells were then washed with PBS and permeabilized in Triton X-100 0.25% for 3 min. Slides were then blocked using 3% BSA and incubated at room temperature in sequential order with deoxyribonuclease I-Alexa Fluor 488 conjugate (Life Technologies, Inc.) and Atto 550-phalloidin (Sigma) to specifically stain G-actin (globular) and F-actin (filaments), respectively. Nuclei were stained with Hoechst 33342.

Cells were visualized under a Zeiss Axiosvert 200 inverted fluorescence microscope (Carl Zeiss, Zaventem, Belgium) at ×40. Images were acquired and processed using the AxioVision LE64 software (Carl Zeiss). For F/G actin quantification, all samples were processed together to avoid changes in the image intensity. Exposure was locked to 100 ms to obtain all acquisitions under the same conditions. ImageJ software was used to measure the pixel intensity of both channels using the whole field of every image. These intensities were used to calculate the F/G actin ratio.

**Confocal Imaging**—Cells samples were observed under a Zeiss LSM780 inverted confocal microscope using ×40/1.1 water objective. Z-stacks of images were acquired sequentially and processed using Zen2010 software (Carl Zeiss).

**Western Blotting**—For Western blotting, cells were washed with cold PBS and lysed using Laemmli Sample Buffer. Total protein was extracted and resolved by 8–12% SDS-PAGE, transferred to a nitrocellulose membrane, and immunoblotted with the specific antibodies for the protein of interest (Table 4) as described (79). Protein signal was visualized using chemiluminescence Supersignal (Pierce). ChemiDoc MP system and Image Lab software version 4.1 (Bio-Rad, Perth, UK) were used for image acquisition and densitometric analysis of the blots. The software allows automatic exposure optimization, ensuring the best use of the dynamic range. Saturation or overexposure is avoided by overriding the images that displayed pixels in red. Densitometric values were corrected by the housekeeping protein α-tubulin as loading control, after background subtraction.

**Statistical Analysis**—Data are shown as means ± S.E. or as independent data points. Significant differences between experimental conditions were assessed by a paired Student’s t test. In case of multiple t test comparisons, the Bonferroni correction was applied as indicated (80). p values < 0.05 were considered statistically significant.
modeling defines the Nova splicing-regulatory network and its combinatorial controls. Science 329, 439–443
48. Leggere, J. C., Saito, Y., Darnell, R. B., Tessier-Lavigne, M., Junge, H. J., and Chen, Z. (2016) NOVA regulates alternative splicing during neuronal migration and axon guidance in the spinal cord. Elife 5, e14264
49. Lovci, M. T., Ghanem, D., Marr, H., Arnold, J., Gee, S., Parra, M., Liang, T. Y., Stark, T. J., Gehman, L. T., Hoon, S., Massirer, K. B., Pratt, G. A., Black, D. L., Gray, J. W., RNA, Conboy, J. G., and Yeo, G. W. (2013) Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges. Nat. Struct. Mol. Biol. 20, 1434–1442
50. Saito, Y., Miranda-Rottmann, S., Ruggiu, M., Park, C. Y., Fak, J. J., Zhong, R., Duncan, J. S., Fabella, B. A., Junge, H. J., Chen, Z., Azara, R., Fritzsche, B., Hudspeth, A. J., and Darnell, R. B. (2016) NOVA2-mediated RNA regulation is required for axonal pathfinding during development. Elife 5, e14371
51. Gehman, L. T., Weeler, E., Wahnich, A., Friedrick, T., Vijayendran, C., Gao, F., Parikshak, N., Konopka, G., and Geschwind, D. H. (2012) RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. Hum. Mol. Genet. 21, 4171–4186
52. Gehman, L. T., Meera, P., Stoilov, P., Shiu, E., O’Brien, J. E., Meisler, M. H., Ares M Jr, Otis, T. S., and Black, D. L. (2012) The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function. Genes Dev. 26, 445–460
53. Bhalla, K., Phillips, H. A., Crawford, J., McKenzie, O. L., Mulley, J. C., Eyre, H., Gardner, A. E., Kremmidiotis, G., and Callen, D. F. (2004) The de novo chromosome 16 translocations of two patients with abnormal phenotypes (mental retardation and epilepsy) disrupt the A2BP1 gene. J. Hum. Genet. 49, 308–311
54. Xu, B., Roos, J. L., Levy, S., van Rensburg, E. J., Gogos, J. A., and Karayiorgou, M. (2008) Strong association of de novo copy number mutations with sporadic schizophrenia. Nat. Genet. 40, 880–885
55. Martin, C. L., Duvall, J. A., Ilkin, Y., Simon, J. S., Duvall, J. A., Ilkin, Y., Simon, J. S., Arreaza, M. G.,Wilkes, K., and Geschwind, D. H. (2007) Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 869–876
56. Sebat, J., Lakshmi, B., Malhotra, D., Tatro, J., Lese-Martin, C., Walsh, T., Tamrakar, B., Yoon, S., Krasnitz, A., Kendall, J., Leotta, A., Pai, D., Zhang, R., Lee, Y. H., Hicks, J., et al. (2007) Strong association of de novo copy number mutations with autism. Science 316, 445–449
57. Pedrotti, S., Giudice, J., Dagnino-Acosta, A., Knoblauch, M., Singh, R. K., Hanna, A. Mo, Q., Hicks, J., Hamilton, S., and Cooper, T. A. (2015) The RNA-binding protein Rbfox1 regulates splicing required for skeletal muscle structure and function. Hum. Mol. Genet. 24, 2360–2374
58. Eliasson, L., Abdulkader, F., Braun, M., Galvanovskis, J., Hoppa, M. B., and Eyre, H. (2001) Inhibition of cytokine-induced NF-
59. Akira, S., Gysemans, C., Mathieu, C., and Eizirik, D. L. (2005) Toll-like receptor 3 and STAT-1 contribute to double-stranded RNA dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 54, 1437–1442
60. Moore, F., Colli, M. L., Cnop, M., Esteve, M. I., Cardozo, A. K., Cunha, D. A., Bugliani, M., Marchetti, P., and Eizirik, D. L. (2009) PTPN2, a candidate gene for type 1 diabetes, modulates interferon-γ-induced pancreatic beta-cell apoptosis. Diabetes 58, 1283–1291
61. Rorsman, P. (2008) Novel aspects of the molecular mechanisms control and amplitude modulation. J. Biol. Chem. 283, 33984–33991
62. Erdinger, M., Piva, F., Dotta, F., Mangi, Y., Helder, S., Anello, M., Bergamini, E., Mosca, F., Di Mario, U., Del Prato, S., and Marchetti, P. (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51, 1418–1427
63. Cardozo, A. K., Ortis, F., Stirling, J., Feng, Y. M., Rasschaert, J., Tonnesen, M., Van Eylen, F., Mandrup-Poulsen, T., Herchuelz, A., and Eizirik, D. L. (2005) The cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 54, 452–461
64. Collin, C., Ladrerie, L., Urbain, M., Mogusan, K., Katabi, B., Sato, S., Akira, S., Gymnich, M., Mathieu, C., and Eizirik, D. L. (2007) Toll-like receptor 3 and STAT-1 contribute to double-stranded RNA+ interferon-γ-induced apoptosis in primary pancreatic beta-cells. J. Biol. Chem. 282, 33984–33991
65. Rorsman, P., Ladrerie, L., Hekerman, P., Ortis, F., Cardozo, A. K., Cunha, Z., Flamez, D., Boyce, M., Yuan, J., and Eizirik, D. L. (2007) Selective inhibition of eukaryotic translation initiation factor 2α dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis. J. Biol. Chem. 282, 3989–3997
66. Wallensten, S., Zucker, C. L., and Fleiss, J. L. (1980) Some statistical methods useful in circulation research. Circ. Res. 47, 1–9